Now Playing
Opinion|Videos|November 9, 2023
KEYNOTE-756: Pembrolizumab Plus Chemo in Early-Stage ER+/HER2- Breast Cancer
Erika P. Hamilton, MD, joins the Oncology Brothers, Rohit Gosain, MD, and Rahul Gosain, MD, to discuss recent data from KEYNOTE-756 investigating pembrolizumab plus chemotherapy in early-stage ER+/HER2- breast cancer.
Advertisement
Advertisement
Related to this article
A phase 2 trial is planned for an allogeneic CAR T-cell product in patients with lung or breast cancer with brain metastases.
The phase 2 NRG-BR002 failed to improve outcomes with targeted radiotherapy to oligometastases; the phase 3 portion will not proceed.
ER status and HER2DX score predict complete response to neoadjuvant THP in HER2-positive breast cancer, guiding smarter, less intensive chemo selection.
The FDA approved tucatinib with trastuzumab and pertuzumab as maintenance therapy in HER2-positive breast cancer, based on median PFS of 24.9 vs 16.3 months in HER2CLIMB-05.
Sarah Premji, MD, of Sarah Cannon Research Institute, discusses community trial access, biomarker-driven drug development, and key breast cancer studies to watch.
Ohio Medicaid patients with breast cancer often miss genomic tests; use stays under 40%, with stage, race, and long-term care status driving disparities.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Durability of PFS and OS Benefit vs. Historical Control
2
Amivantamab vs. Emerging EGFR Bispecifics in HNSCC
3
How Disease Burden Shapes First-Line RCC Treatment Selection
4
Rivoceranib Plus Camrelizumab Resubmitted to FDA in Frontline HCC
5